CN109069535B - 突变型博德特氏菌属菌株及其使用方法 - Google Patents

突变型博德特氏菌属菌株及其使用方法 Download PDF

Info

Publication number
CN109069535B
CN109069535B CN201780021384.7A CN201780021384A CN109069535B CN 109069535 B CN109069535 B CN 109069535B CN 201780021384 A CN201780021384 A CN 201780021384A CN 109069535 B CN109069535 B CN 109069535B
Authority
CN
China
Prior art keywords
subject
development
preventing
airway inflammation
reducing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780021384.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN109069535A (zh
Inventor
路易斯·索兰斯
卡米尔·洛赫特
安妮·蒂斯科普洛斯
萨利哈·艾特雅希亚森迪德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur de Lille
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut Pasteur de Lille
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur de Lille, Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut Pasteur de Lille
Priority to CN202210315642.5A priority Critical patent/CN114767718A/zh
Publication of CN109069535A publication Critical patent/CN109069535A/zh
Application granted granted Critical
Publication of CN109069535B publication Critical patent/CN109069535B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physiology (AREA)
  • Developmental Biology & Embryology (AREA)
CN201780021384.7A 2016-03-29 2017-03-29 突变型博德特氏菌属菌株及其使用方法 Active CN109069535B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210315642.5A CN114767718A (zh) 2016-03-29 2017-03-29 突变型博德特氏菌属菌株及其使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662314843P 2016-03-29 2016-03-29
US62/314,843 2016-03-29
PCT/EP2017/057468 WO2017167834A1 (en) 2016-03-29 2017-03-29 Mutant bordetella strains and methods for use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210315642.5A Division CN114767718A (zh) 2016-03-29 2017-03-29 突变型博德特氏菌属菌株及其使用方法

Publications (2)

Publication Number Publication Date
CN109069535A CN109069535A (zh) 2018-12-21
CN109069535B true CN109069535B (zh) 2022-03-18

Family

ID=58488973

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780021384.7A Active CN109069535B (zh) 2016-03-29 2017-03-29 突变型博德特氏菌属菌株及其使用方法
CN202210315642.5A Pending CN114767718A (zh) 2016-03-29 2017-03-29 突变型博德特氏菌属菌株及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210315642.5A Pending CN114767718A (zh) 2016-03-29 2017-03-29 突变型博德特氏菌属菌株及其使用方法

Country Status (10)

Country Link
US (4) US10682377B2 (cg-RX-API-DMAC7.html)
EP (2) EP3436034B1 (cg-RX-API-DMAC7.html)
JP (1) JP6993984B2 (cg-RX-API-DMAC7.html)
CN (2) CN109069535B (cg-RX-API-DMAC7.html)
AU (2) AU2017242541B2 (cg-RX-API-DMAC7.html)
DK (1) DK3436034T3 (cg-RX-API-DMAC7.html)
ES (1) ES3027194T3 (cg-RX-API-DMAC7.html)
FI (1) FI3436034T3 (cg-RX-API-DMAC7.html)
SG (1) SG11201807783UA (cg-RX-API-DMAC7.html)
WO (1) WO2017167834A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2821830T3 (es) 2006-03-10 2021-04-27 Pasteur Institut Cepas de Bordetella vivas atenuadas como vacuna de dosis única contra la tos ferina
DK2424564T3 (en) 2009-04-28 2015-04-27 Inserm Inst Nat De La Santé Et De La Rech Médicale A vaccine for the prevention or treatment of a respiratory pathology allergendrevet
WO2017167834A1 (en) * 2016-03-29 2017-10-05 Institut Pasteur De Lille Mutant bordetella strains and methods for use
CN111278456B (zh) 2017-10-18 2024-08-09 里尔巴斯德研究所 表达血清3型菌毛的鲍特菌属菌株
EP4196155A4 (en) 2020-08-14 2025-03-19 Iliad Biotechnologies, LLC Lyophilized live bordetella vaccines
EP4247397A4 (en) 2020-11-17 2024-11-06 Iliad Biotechnologies, LLC TREATMENT AND PREVENTION OF NEUROPATHOLOGY ASSOCIATED WITH NEURODEGENERATIVE DISEASES
CA3261556A1 (en) 2022-07-22 2024-01-25 Institut National de la Santé et de la Recherche Médicale USE OF BORDETELLA STRAINS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
WO2025257397A1 (en) 2024-06-14 2025-12-18 Institut National de la Santé et de la Recherche Médicale Live attenuated bordetella vaccines capable of producing and secreting heterologous antigens

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1184459A2 (en) * 1991-07-16 2002-03-06 Aventis Pasteur Limited Manipulation of gene copy number in Bordetella
US6660261B1 (en) * 1996-10-11 2003-12-09 Institut Pasteur De Lille Bordetella strain expressing the FHA hybrid, liposomes and vaccines
CN102448490A (zh) * 2009-04-28 2012-05-09 国家健康与医学研究院 用于预防或治疗过敏原引起的气道疾病的疫苗
CN104302314A (zh) * 2011-11-02 2015-01-21 新加坡国立大学 减毒博代氏杆菌菌株对抗变应性疾病的效果

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713072B1 (en) 1987-11-02 2004-03-30 Chiron S.R.L. Immunologically active polypeptides with altered toxicity useful for the preparation of an antipertussis vaccine
FR2718750B1 (fr) 1994-04-19 1996-06-14 Pasteur Institut Protéines recombinantes de l'hémagglutinine filamenteuse de Bordetella, notamment, B. Pertussis, production et application à la production de protéines étrangères ou de principes actifs vaccinants.
DE69511392T2 (de) * 1994-04-28 2000-03-23 Takeda Chemical Industries, Ltd. Verfahren zur trennung von protektiven verbindungen aus bordetella pertussis
FR2840319B1 (fr) 2002-05-30 2004-08-20 Pasteur Institut Souches de bordetella rendues deficientes par attenuation genetique
AU2004229527B2 (en) 2003-04-11 2009-08-20 Medimmune, Llc Methods of preventing or treating respiratory conditions
ES2821830T3 (es) 2006-03-10 2021-04-27 Pasteur Institut Cepas de Bordetella vivas atenuadas como vacuna de dosis única contra la tos ferina
JP2010508860A (ja) 2006-11-15 2010-03-25 フォリア バイオテック インコーポレイテッド パパイヤモザイクウイルスに基づくインフルエンザ用ワクチン
WO2008118592A2 (en) 2007-02-23 2008-10-02 The Penn State Research Foundation Use of an avirulent bordetella mutant as a live vaccine vector
AU2008266910A1 (en) 2007-06-18 2008-12-24 Hemispherx Biopharma, Inc. Early intervention of viral infections with immune activators
WO2010146414A1 (en) 2009-06-15 2010-12-23 National University Of Singapore Influenza vaccine, composition, and methods of use
CN102793915B (zh) * 2012-07-25 2013-10-23 天津康希诺生物技术有限公司 一种无细胞百日咳疫苗的生产方法
EP2722338A1 (en) 2012-10-17 2014-04-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel recombinant Bordetella strains
WO2017167834A1 (en) * 2016-03-29 2017-10-05 Institut Pasteur De Lille Mutant bordetella strains and methods for use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1184459A2 (en) * 1991-07-16 2002-03-06 Aventis Pasteur Limited Manipulation of gene copy number in Bordetella
US6660261B1 (en) * 1996-10-11 2003-12-09 Institut Pasteur De Lille Bordetella strain expressing the FHA hybrid, liposomes and vaccines
CN102448490A (zh) * 2009-04-28 2012-05-09 国家健康与医学研究院 用于预防或治疗过敏原引起的气道疾病的疫苗
CN104302314A (zh) * 2011-11-02 2015-01-21 新加坡国立大学 减毒博代氏杆菌菌株对抗变应性疾病的效果

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Bordetella pertussis and pertactin-deficient clinical isolates: lessons for pertussis vaccines;Nicolas Hegerle等;《Expert Review of Vaccines》;20140623;第13卷(第9期);第1141页左栏倒数第2段 *
Bordetella pertussis Strain Lacking Pertactin and Pertussis Toxin;Margaret M. Williams等;《Emerg Infect Dis》;20160229;第22卷(第2期);全文 *

Also Published As

Publication number Publication date
US20200323901A1 (en) 2020-10-15
ES3027194T3 (en) 2025-06-13
US20210290667A1 (en) 2021-09-23
US10682377B2 (en) 2020-06-16
AU2017242541A1 (en) 2018-10-11
EP4541809A3 (en) 2025-06-25
US20230381224A1 (en) 2023-11-30
WO2017167834A1 (en) 2017-10-05
CN109069535A (zh) 2018-12-21
US20170283890A1 (en) 2017-10-05
AU2017242541B2 (en) 2022-06-30
EP4541809A2 (en) 2025-04-23
AU2022221438B2 (en) 2024-10-03
US11065276B2 (en) 2021-07-20
JP2019513722A (ja) 2019-05-30
DK3436034T3 (da) 2025-05-12
EP3436034B1 (en) 2025-03-26
FI3436034T3 (fi) 2025-05-08
SG11201807783UA (en) 2018-10-30
EP3436034A1 (en) 2019-02-06
CN114767718A (zh) 2022-07-22
AU2022221438A1 (en) 2022-10-06
CA3018126A1 (en) 2017-10-05
JP6993984B2 (ja) 2022-02-03

Similar Documents

Publication Publication Date Title
CN109069535B (zh) 突变型博德特氏菌属菌株及其使用方法
Barbic et al. Role of gamma interferon in natural clearance of Bordetella pertussis infection
JP2019513722A5 (cg-RX-API-DMAC7.html)
US12403188B2 (en) Bordetella strains expressing serotype 3 fimbriae
JP2005112865A (ja) 百日咳菌ワクチン用アジュバントとしてのｉｌ−１２
WO2020049133A1 (en) Adenylate cyclase catalytic domain deficient bordetella strains
Mann et al. Use of a genetically defined double mutant strain of Bordetella bronchiseptica lacking adenylate cyclase and type III secretion as a live vaccine
JP2001507568A (ja) ハイブリッドｆｈａを発現するボルデテラ株、リポソームおよびワクチン
CA3018126C (en) Mutant bordetella strains and methods of use
HK1262896A1 (en) Mutant bordetella strains and methods for use
HK1262896B (zh) 突变型博德特氏菌属菌株及其使用方法
JP6867623B2 (ja) 百日咳モデル動物およびその作製方法、ならびに百日咳モデル動物を用いた方法
Yount Improved vaccines against Bordetella pathogens utilizing Th1/17-polarizing adjuvant BcfA and mucosal immunization strategies
KR20250038747A (ko) 만성 폐쇄성 폐질환의 치료를 위한 보르데텔라 균주의 용도
CN101400783B9 (zh) 包特氏菌减毒活菌株作为抗百日咳的单剂量疫苗
Pilione et al. Use of a Genetically Defined Double Mutant
HK40026630B (zh) 表达血清3型菌毛的鲍特菌属菌株
Goel Interleukin-6 Contributes To Immunity Against Bordetella Pertussis.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1262896

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant